Determinants for successful smoking cessation with bupropion in daily practice

被引:1
|
作者
Bouvy, ML
Buurma, H
Egberts, ACG
机构
[1] SIR Inst Pharm Practice Res, NL-2331 JE Leiden, Netherlands
[2] Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[3] Hosp Pharm Midden Brabant, Tweesteden, Netherlands
[4] St Elizabeth Hosp, Tilburg, Netherlands
来源
PHARMACY WORLD & SCIENCE | 2003年 / 25卷 / 05期
关键词
bupropion; clinical practice; smoking cessation;
D O I
10.1023/A:1025892031198
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: to describe the patterns of use of bupropion in daily clinical practice and factors which determine successful smoking cessation. Methods: Retrospective follow-up study in 36 pharmacies in the Netherlands. Patients who received at least one prescription for bupropion between January and April, 2000 were included. The pharmacists noted several characteristics relating to the patient, use of bupropion and co-medication. Patients were interviewed by telephone about their current and former smoking habits, the success of their smoking cessation and their experiences with bupropion. Main outcome measure: Abstinence rate and factors determining successful abstinence after six months. Results: 322 patients with a least one prescription for bupropion were identified. In 93.5% of patients bupropion was prescribed by the general practitioner. Half of the patients were dispensed 30 or fewer tablets. Pharmacists interviewed 215 (66.8%) patients by telephone. Of these patients 58 (27.0%) still did not smoke six months after the prescription for bupropion. The number of tablets used, lack of co-morbidity, less than two previous attempts to stop smoking and private-insurance were associated with a higher rate of successful abstinence. Conclusion: Most patients do not use bupropion in accordance with the recommended period and did not receive the same degree of additional support provided in clinical trials. Nevertheless 27.0% of patients reported to have stopped smoking six months after the prescription for bupropion. This self-reported abstinence rate is only slightly lower than is reported in literature. This might be partly related to the fact that we did not validate smoking cessation by carbonmonoxide monitoring. Bupropion is not reimbursed in the Netherlands. It is difficult to assess whether patients' self-payment has led to the selection of motivated patients, or has been a barrier to finishing using bupropion.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 50 条
  • [1] Determinants for successful smoking cessation with bupropion in daily practice
    M.L. Bouvy
    H. Buurma
    A.C.G. Egberts
    Pharmacy World and Science, 2003, 25 : 207 - 211
  • [2] Bupropion for smoking cessation - Predictors of successful outcome
    Dale, LC
    Glover, ED
    Sahs, DPL
    Schroeder, DR
    Offord, KP
    Croghan, IT
    Hurt, RD
    CHEST, 2001, 119 (05) : 1357 - 1364
  • [3] Review of bupropion for smoking cessation
    Richmond, R
    Zwar, N
    DRUG AND ALCOHOL REVIEW, 2003, 22 (02) : 203 - 220
  • [4] Smoking cessation pharmacotherapy; varenicline or bupropion?
    Rahimi, Fatemeh
    Massoudifar, Ali
    Rahimi, Roya
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 32 (02) : 901 - 906
  • [5] Bupropion SR for smoking cessation
    West, R
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 533 - 540
  • [6] Clinical Efficacy of Bupropion in the Management of Smoking Cessation
    Douglas Jorenby
    Drugs, 2002, 62 : 25 - 35
  • [7] Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
    Stapleton, John
    West, Robert
    Hajek, Peter
    Wheeler, Jenny
    Vangeli, Eleni
    Abdi, Zeinab
    O'Gara, Colin
    McRobbie, Hayden
    Humphrey, Kirsty
    Ali, Rachel
    Strang, John
    Sutherland, Gay
    ADDICTION, 2013, 108 (12) : 2193 - 2201
  • [8] Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice
    Federico Giulietti
    Andrea Filipponi
    Giulia Rosettani
    Piero Giordano
    Corrado Iacoacci
    Francesco Spannella
    Riccardo Sarzani
    High Blood Pressure & Cardiovascular Prevention, 2020, 27 : 349 - 362
  • [9] Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice
    Giulietti, Federico
    Filipponi, Andrea
    Rosettani, Giulia
    Giordano, Piero
    Iacoacci, Corrado
    Spannella, Francesco
    Sarzani, Riccardo
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2020, 27 (05) : 349 - 362
  • [10] A placebo controlled trial of bupropion for smoking cessation in schizophrenia
    George, TP
    Vessicchio, JC
    Termine, A
    Bregartner, TA
    Feingold, A
    Rounsaville, BJ
    Kosten, TR
    BIOLOGICAL PSYCHIATRY, 2002, 52 (01) : 53 - 61